research ODP342 Panhypopituitarism Induced by CTLA-4 and PD-1/PD-L1 Inhibitor Immunotherapy
Immunotherapy for cancer caused a patient to develop a condition affecting hormone production, requiring ongoing hormone replacement therapy.
Search
for
Sort by
Research
930-960 / 1000+ results research CRISPR/Cas9-mediated Generation ofCOL7A1-deficient Keratinocyte Model of Recessive Dystrophic Epidermolysis Bullosa
Scientists created cell lines to study a genetic skin disorder using CRISPR technology.
research Multiplex matrix network analysis of protein complexes in the human TCR signalosome
Alopecia areata patients show unique protein activity patterns, suggesting imbalanced signaling pathways.
research Switching between tofacitinib and baricitinib in alopecia areata: A review of clinical response
Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.
research IMMUNE-RELATED SKIN TOXICITIES TO CHECKPOINT INHIBITORS THERAPY
Checkpoint inhibitor therapy can cause skin issues, from mild rashes to severe reactions.
research Two Birds that Exclude Each Other: The Renbök Phenomenon
Oral tofacitinib can treat both psoriasis and alopecia universalis by normalizing inflammatory pathways.
research Targeting cardiac hypertrophy through a nuclear co‐repressor
Targeting NCoR1 can help treat heart enlargement and dysfunction.
research Answer
Cyclosporine-A can cause excessive hair growth, which usually stops after discontinuing the drug.
research USE OF RITLECITINIB FOR THE TREATMENT OF ALOPECIA AREATA
Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
research Autophagy-related protein 12 associates with anti-apoptotic B cell lymphoma-2 to promote apoptosis in gentamicin-induced inner ear hair cell loss
Blocking autophagy increases survival of inner ear hair cells exposed to gentamicin.
research 022 Exploring the potential of the novel IFNγ aptamer TAGX-0003 as a treatment for alopeciaareata in pre-clinical models
The new aptamer TAGX-0003 shows promise as an effective treatment for hair loss disorder alopecia areata.
research Management of comorbid Crohn's disease and alopecia universalis with upadacitinib and oral minoxidil.
Upadacitinib and oral minoxidil improved Crohn's disease and hair regrowth in a patient.
research Association of prior 5-α-reductase inhibitor exposure with ICI benefit in metastatic RCC: Multicentre cohort with single-cell immune profiling.
Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.
research S3886 Concurrent Management of Crohn's Ileitis and Alopecia Universalis With Upadacitinib
Upadacitinib improved both Crohn's ileitis and alopecia universalis in a patient.
research Use of Contact Immunotherapy in the Treatment of Skin Diseases Other than Alopecia Areata
Contact immunotherapy might help treat various skin conditions, but more research is needed to confirm its safety and effectiveness.
research 1495 Dimethyl fumarate ameliorates delayed wound healing due to IL-36Ra deficiency through inhibition of NET formation and oxidative stress
Dimethyl fumarate speeds up wound healing in IL-36Ra deficient mice by reducing NET formation and oxidative stress.
research P718 Observational real-world evidence on the efficacy and safety of Janus Kinase inhibitors (JAKi) in the treatment of moderate to severe Active Ulcerative Colitis (UC)
Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.
research Double mutation of claudin‐1 and claudin‐3 causes alopecia in infant mice
Mutations in claudin-1 and claudin-3 cause hair loss in baby mice.
research Case Report: Bimekizumab for dissecting cellulitis of the scalp
Bimekizumab effectively treats scalp cellulitis and improves quality of life.
research LB919 Increased risk of skin cancer and other malignancies in patients with cutaneous lupus erythematous
Patients with cutaneous lupus erythematosus have a higher risk of skin cancer and other cancers.
research Efficacy and safety of ritlecitinib, an oral JAK3 /TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis
Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.
research Cystatin M/E Is a High Affinity Inhibitor of Cathepsin V and Cathepsin L by a Reactive Site That Is Distinct from the Legumain-binding Site
Cystatin M/E strongly inhibits cathepsin V and cathepsin L, important for skin formation.
research Alopecia areata and ritlecitinib: Unravelling response trajectories
Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.
research Mycobacterial 65,000 MW heat-shock protein shares a carboxy-terminal epitope with human epidermal cytokeratin 1/2.
A mycobacterial protein shares a similar region with a human skin protein, possibly affecting skin diseases.
research Detection of lentiviral constructs for release testing of CAR- T cells using digital droplet PCR
The new ddPCR method reliably detects unwanted viruses in CAR-T cell products, ensuring their safety for patients.
research Suppression of Cutibacterium acnes-Mediated Inflammatory Reactions by Fibroblast Growth Factor 21 in Skin
FGF21 can help reduce skin inflammation caused by C. acnes.
research P0881 Effectiveness and Safety of Tofacitinib in Biologic-Naïve Elderly Patients with Ulcerative Colitis
Tofacitinib is effective and safe for elderly patients with ulcerative colitis.
research Homozygous whole body Cbs knockout in adult mice features minimal pathology during ageing despite severe homocysteinemia
Adult mice with CBS deficiency show minimal health issues and normal lifespan despite high homocysteine levels.
research Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors
Cancer patients treated with immune checkpoint inhibitors may develop alopecia, but some hair regrowth is possible with treatment.
research Small cell lung cancer: Results of a phase II study of 1,2,4 triglycidylurazol
The drug TGU was ineffective against small cell lung cancer and caused significant bone marrow suppression.